|
Ek, O; Reaman, G H; Crankshaw, D L et al. (1998) Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia. Leuk Lymphoma 28:509-14
|
|
Uckun, F M; Yanishevski, Y; Tumer, N et al. (1997) Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys. Clin Cancer Res 3:325-37
|
|
Waurzyniak, B; Schneider, E A; Tumer, N et al. (1997) In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 3:881-90
|
|
Messinger, Y; Yanishevski, Y; Avramis, V I et al. (1996) Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside. Clin Cancer Res 2:1533-42
|
|
Gunther, R; Chelstrom, L M; Wendorf, H R et al. (1996) Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Leuk Lymphoma 22:61-70, follow.186, color plate
|
|
Uckun, F M; Reaman, G H (1995) Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 18:195-201
|
|
Myers, D E; Yanishevski, Y; Masson, E et al. (1995) Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule. Leuk Lymphoma 18:93-102
|
|
Uckun, F M; Myers, D E (1993) Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies. J Hematother 2:155-63
|
